You’ve seen it before: A medical device company with around 200 employees selects an enterprise quality and regulatory platform built to support more than 5,000 employees. “If it’s good enough for J&J, it’s good enough for us,” goes the thinking. Three years later, implementation is nowhere near complete, costs have ballooned to several times the original budget, and the organization is using maybe 30% of what they paid for.

This isn’t about failed execution. This is about bad starting assumptions; specifically, the assumption that medtech and pharma are the same industry on different points of a maturity spectrum, and that technology built for large pharmaceutical companies represents the pinnacle to which every device company should aspire. It doesn’t work that way, and trying to force that model creates problems.

Different industries, not maturity levels

Understanding the MedTech Advantage

Medical devices and pharmaceuticals are routinely grouped together within life sciences. It’s understandable; both industries operate under regulatory scrutiny and both have patient safety in their veins. But assuming medtech and pharma exist on the same continuum stretches far beyond where similarities end and the fundamentals of each business diverge.

Consider regulatory pathways. The FDA’s 510(k) submissions are not New Drug Applications with different-colored covers. Medical device and pharmaceutical regulatory processes are built around different evidence models, risk profiles and review frameworks. Device classification and traceability requirements differ fundamentally from pharmaceutical approval pathways. Likewise, post-market surveillance reflects these differences: Medical devices rely heavily on performance data, device failures and real-world use signals, while pharmaceutical oversight places greater emphasis on adverse events, safety signals and clinical outcomes.

The business models differ as well. Products come to market faster on a device timeline than they do in pharma, typically iterating every two-to-five years vs. pharma’s over-10-year timeline. Devices are manufactured much more discretely than chemical batches. Distributing a device into the world requires service, parts and user training considerations that pills don’t have to account for.

Those differences radiate outward to the systems each industry builds inside their four walls. Pharma companies typically start with safety systems, then layer on regulatory compliance to then connect to production. Device companies lean much more heavily on quality from day one, with design controls built into the earliest stages of product development. And in every category that intersects software — whether that’s software-driven devices, connected diagnostics or true combination products — medtech is not playing catch-up to pharma; they’re resetting the innovation curve.

How the enterprise trap is set

If medtech and pharma are so fundamentally different, how do device companies keep finding themselves at the altar with enterprise-scale platforms designed for the world’s largest life sciences organizations? It starts with familiar-seeming decisions that no one intends any ill effect from.

Words like “industry standard” and “best practices” are defined by the industries that spend the most money on technology, which is typically pharmaceutical and biotech. Internal RFPs tend to mirror the outsized contracts big companies use; few device companies ask themselves if they need an on-premise solution or a license that integrates with Salesforce. Consultants tend to implement what they know, which if they’ve worked in life sciences, is most likely pharma. Solution vendors position their enterprise, enterprise-plus or custom solutions as the Cadillac option. At some point, someone asks why the company doesn’t have what another well-known pharmaceutical organization has.

Predictable problems follow predictable causes. Pharma-centric feature sets that were never used sit collecting dust at device companies that don’t file NDAs. Implementation timelines built for organizations with six-figure IT teams take 18 months or more when quality and regulatory share a single analyst. Employees who should be using the system quit trying because training materials don’t apply to their workflows and IT support takes months to respond to tickets. Costs inevitably come in two- or three-times the initial estimates because “that’s what software costs.” Companies that were months away from launching a product transition directly into troubleshooting mode. By the time someone notices things aren’t going according to plan, startups that passed on the “enterprise solution” have shipped multiple products.

What right-sized actually looks like

This is not an argument for slack quality systems and late submissions. Devices and drugs are regulated for a reason, and compliance software should help teams do their jobs well. But the difference between right-sized and enterprise solutions is matching the tool to the job.

The right technology for a growing medical device company means something that can stand up software that runs in weeks, not years. It means a system that matches their workflows rather than assuming every organization needs the same features. It also means buying technology that works for lean teams.

Did you know there are still software vendors selling “named user” licensing for medical device teams? Device companies need concurrent, usage-based licensing that grows with them. They need interfaces that don’t require a dedicated administrator because quality and regulatory share a single employee. They need mobile-accessibility for quality engineers who spend their days on the shop floor instead of at desks.

Right-sized doesn’t mean you can never grow into something larger. The ideal platform will add new modules and capacity as you hire more people. Just as critically, it’ll support new geographies as you expand globally and absorb new product lines cleanly if you grow through acquisition. It just means you don’t pay for that scale until you need it.

All of the benefits of getting this decision right multiply over time. Streamlined submissions mean your company can shorten its path to market when every day counts. Meanwhile, lower software costs mean you have money to reinvest into R&D, clinical studies or expanding into adjacent markets. Those benefits alone can extend the life of a VC-backed company by a year or more. Teams that don’t have to struggle with their own technology can pivot when regulations change or a competitor jumps into the space. They actually spend their time doing regulatory work, not administering and troubleshooting software.

What to consider before your next technology purchase

Thinking through your next platform purchase? Here are a few ways to weed-out the sales hype and counter internal bias to keep up with the big companies.

Look to device companies comparable to you in size, not big pharma. Every tool on a vendor’s platform should be justifiable by asking, “Does this solve a medtech problem?” If the answer is no, keep asking questions. When speaking with references, talk to customers at your size now, not where you want to be in five years. This isn’t a box to check at the end of product development; it’s a strategic decision that will shape how your company works for the next decade.

Even if you worry it’ll be outgrown quickly, modern systems are built to scale; you add capabilities as your organization grows rather than replacing what you have. It’s also far easier and cleaner to migrate a well-run system that was properly scaled to your processes into a large pharma organization than it is to pick apart customized enterprise software made to support the workflows of a completely different company.

The real competitive advantage

Life sciences convergence is real. Software as a medical device, companion diagnostics and combination products are creating genuine overlap between traditional device and pharmaceutical models. That doesn’t mean medtech and pharma should be forced onto the exact same platforms. It does mean technology needs to flex at the intersection where the two industries overlap, without enforcing broad standards from one side onto the other.

Speed and agility are the competitive advantages that enterprise solutions were never designed to protect. You can’t have those if you’re adopting technology designed for the biggest companies in the industry. Your technology decision will dictate your company’s future trajectory for the next five to 10 years, so it’s key to devote significant resources to this process.

Editor’s Note:  Mike King, Senior Director, Product and Strategy (Quality, Regulatory, Safety & Detect), Digital Products and Solutions, IQVIA. With over 20 years of experience leading global teams in quality assurance and regulatory affairs, Mike King, as Senior Director of Product and Strategy at IQVIA, ensures healthcare solutions meet complex global regulations and oversees platforms like SmartSolve® eQMS and RIM Smart to streamline quality and regulatory compliance processes.